Work

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Year: 2009

Type: article

Source: Blood

DOI: 10.1182/blood.v114.22.584.584

Authors: Nam H. Dang, Mitchell R Smith, Fritz Offner, Gregor Verhoef, Peter Johnson, Ama Z S Rohatiner, Jonathan L. Kaufman, Eva Gine, Bertrand Coiffier, Myron S Czuczman, James Foran, Simon Durrant, Steven Hua, Erik R. Vandendries, Luis Fayad

Institutions: UF Health Cancer Center, Fox Chase Cancer Center, Ghent University Hospital, Universitair Ziekenhuis Leuven, Cancer Research UK, University of Southampton, St Bartholomew's Hospital, Emory University, Winship Cancer Institute, Hospital Clínic de Barcelona, Hôpital Lyon Sud, Roswell Park Comprehensive Cancer Center, University of Alabama at Birmingham, Royal Brisbane and Women's Hospital, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2245173676

FWCI: 5.131

Cites:

Cited by: 29

Related to: 10